PCM
SPRY icon

Permanent Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Permanent Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
43,383
+8,268
+24% +$71.1K 0.05% 126
2026
Q1 		$290K Sell
35,115
-17,191
-33% -$165K 0.05% 123
2025
Q4 		$609K Sell
52,306
-1,035
-2% -$10.1K 0.12% 77
2025
Q3 		$536K Buy
+53,341
New +$766K 0.1% 81
2024
Q2 		$744K Buy
+42,623
New +$378K 0.16% 65

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Permanent Capital Management's SPRY Position: Q2 2026 in Review

Permanent Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 24% in Q2 2026, buying an estimated $71.1K and bringing the position to 43,383 shares worth $347K. The position accounts for 0.05% of the portfolio, ranked #126.

Permanent Capital Management first reported a position in SPRY in Q2 2024 and has held it in 5 quarters since. The position peaked at $744K in Q2 2024. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Permanent Capital Management held 43,383 shares of ARS Pharmaceuticals worth $347K as of Q2 2026.
  • Permanent Capital Management bought 8,268 ARS Pharmaceuticals shares in Q2 2026, an estimated $71.1K.
  • ARS Pharmaceuticals made up 0.05% of Permanent Capital Management's portfolio in Q2 2026, its #126 holding.
  • Permanent Capital Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Permanent Capital Management's ARS Pharmaceuticals position peaked at $744K in Q2 2024.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Permanent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.